Serum FAM19A5 in neuromyelitis optica spectrum disorders: Can it be a new biomarker representing clinical status?

Hye Lim LeeHung Youl SeokHan-Wook RyuEun Bee ChoBong Chul KimByoung Joon KimJu-Hong MinJin Myoung SeokHa Young ShinSa-Yoon KangOh-Hyun KwonSang-Soo LeeJeeyoung OhEun-Hee SohnSo-Young HuhJoong-Yang ChoJae Young SeongByung-Jo Kim

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)

Serum FAM19A5 was higher in patients with NMOSD-AQP4 and correlated with clinical characteristics. Thus, serum FAM19A5 may be a novel clinical biomarker for NMOSD-AQP4.

Keyphrases